Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233947 · ClinicalTrials.gov registry record · Phase 2
Study of AFP464 +/- Faslodex in ER + Breast Cancer
A Phase 2 study, sponsored by Tigris Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01233947: Clinical Trial Phase 2 study, sponsored by Tigris Pharmaceuticals.
NCT01233947 is a Phase 2 study that was terminated before completion, run by Tigris Pharmaceuticals. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01233947, a Phase 2 study, was terminated before completion, sponsored by Tigris Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.
Primary Outcome
Clinical Benefit Response (CBR) defined as Complete Response, Partial Response or Stable Disease for 6 months.
Interventions
- DRUG AFP464
- DRUG AFP464 + Faslodex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Why NCT01233947 stopped before completion
NCT01233947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which AFP464 is the first listed.
NCT01233947 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01233947 about?
NCT01233947 is a clinical study titled "Study of AFP464 +/- Faslodex in ER + Breast Cancer". AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.
What is the current status of trial NCT01233947?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2011-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01233947?
The interventions under investigation include: AFP464 (DRUG), AFP464 + Faslodex (DRUG).
Who is sponsoring clinical trial NCT01233947?
This trial is sponsored by Tigris Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01233947's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia